How Long Does Lacosamide Stay in Your System?

Lacosamide has a plasma half-life of about 13 hours in most adults, which means it takes roughly three days for your body to clear the drug after your last dose. Full elimination, including metabolites, stretches closer to seven days based on excretion studies. That timeline shifts meaningfully if you have kidney or liver problems, take certain other seizure medications, or fall outside the typical adult age range.

The 13-Hour Half-Life and What It Means in Practice

A drug’s half-life is the time it takes for its concentration in your blood to drop by half. For lacosamide, that number is approximately 13 hours in younger adults and around 14 to 16 hours in older adults, a difference that generally does not require a change in dosing schedule.¹ This is why lacosamide is typically taken twice a day: two roughly equal doses spaced about 12 hours apart keep blood levels in a steady therapeutic range.²

After your last dose, it generally takes five to six half-lives for a drug to be considered functionally gone from your system. With a 13-hour half-life, that works out to about 65 to 78 hours, or roughly three days. By that point, the amount of lacosamide circulating in your blood is too small to have any meaningful pharmacological effect. However, trace amounts of the drug and its breakdown products can linger somewhat longer, particularly in urine.

How Your Body Gets Rid of Lacosamide

Lacosamide leaves your body almost entirely through your kidneys. A detailed human excretion study found that after an oral dose, about 94% of the drug and its metabolites were recovered in urine within seven days, with less than half a percent appearing in feces.³ This heavy reliance on renal clearance is a key reason kidney function matters so much for how long the drug sticks around.

Not all of the lacosamide that reaches your urine is unchanged drug. Roughly a third leaves the body as intact lacosamide, another 28% is converted to a metabolite called O-desmethyl-lacosamide, and the rest appears as smaller polar breakdown products.³ The liver handles the metabolic conversion, but the kidneys do the heavy lifting of flushing everything out.

After an oral dose, blood concentrations drop by about 65% within the first 24 hours.³ That steep initial decline is reassuring if you are worried about how quickly the drug clears, but it also underscores why missing a dose can cause a noticeable dip in protection against seizures.

When Kidney Problems Slow Things Down

Because the kidneys handle the vast majority of lacosamide excretion, impaired kidney function directly extends the drug’s stay in your system. Studies in people with reduced kidney function show that the half-life gets longer, total drug exposure goes up, and the rate at which the kidneys clear the drug drops.⁴ In practical terms, the drug hangs around at higher concentrations for longer, which raises the risk of side effects like dizziness, double vision, and nausea.

For people on dialysis, the picture gets more complex. Hemodialysis can pull lacosamide out of the blood. One case report of a severe overdose showed that a four-hour hemodialysis session dropped blood levels from 68.1 to 18.3 micrograms per milliliter.⁵ This means that patients receiving regular hemodialysis may need supplemental doses after their dialysis sessions to keep therapeutic levels up. Continuous renal replacement therapy, a type of round-the-clock kidney support used in intensive care, also significantly affects lacosamide dosing because clearance rates shift with the patient’s body weight and how the machine is calibrated.⁶

Liver Impairment and Lacosamide Clearance

Although the kidneys do the bulk of the excretion work, the liver plays a role in metabolizing lacosamide before it reaches the urine. Preclinical research has shown that experimentally induced liver damage increases the total drug exposure in the bloodstream, meaning the drug is cleared more slowly and reaches higher peak levels than it would in someone with healthy liver function.⁷

A pharmacokinetic modeling study quantified the dose adjustments likely needed for people with different degrees of liver impairment. It estimated that patients with mild liver impairment might need around 89% of the standard healthy-adult dose, those with moderate impairment about 72%, and those with severe impairment only about 36%.⁸ Those numbers give you a sense of how much longer the drug effectively stays active when the liver cannot process it at full speed. If you have known liver disease, your doctor will likely prescribe a lower dose and may want to monitor blood levels more closely.

How Other Seizure Medications Change the Timeline

One of lacosamide’s selling points is its generally low potential for drug interactions.⁹ But “low” is not “zero.” Certain older anti-seizure drugs speed up the liver enzymes that break down lacosamide, which means the drug gets cleared faster and its blood levels fall. A study measuring trough concentrations found that carbamazepine lowered lacosamide levels by about 30%, phenytoin by 32%, primidone by 34%, phenobarbital by 39%, and methsuximide by 41%.¹⁰ In children, the effect was even more pronounced.

What this means for how long lacosamide stays in your system is straightforward: if you are also taking one of these enzyme-inducing drugs, lacosamide leaves faster. A population pharmacokinetic study in Chinese children and adults found that co-administration of phenobarbital or carbamazepine increased lacosamide clearance by a factor of about 1.42.¹¹ That same study found that body weight and kidney-function markers also independently affected how quickly the drug was eliminated. If you switch on or off one of these interacting medications, your lacosamide levels will shift, and your neurologist may adjust your dose accordingly.

By contrast, several newer anti-seizure drugs, including oxcarbazepine, eslicarbazepine, and valproate, had little to no impact on lacosamide blood levels.¹⁰ So the choice of companion drug matters when estimating how long lacosamide will linger.

Detecting Lacosamide in Saliva and Urine

Blood draws are the standard way to check lacosamide levels, but the drug also shows up in saliva and urine. A pharmacokinetic study that tracked lacosamide and its major metabolite across plasma, saliva, and urine found measurable drug in saliva samples collected out to 72 hours after dosing and in urine collected over 48 hours.¹² Saliva testing has been explored as a less invasive alternative to blood draws, particularly for routine monitoring in children or people with difficult venous access.

If you are wondering whether lacosamide would show up on a standard workplace drug screen, the answer is almost certainly no. Standard urine panels test for drugs of abuse like amphetamines, opioids, and benzodiazepines, and lacosamide does not cross-react with those assays. A specialized test would be needed to identify it specifically.

Switching Between IV and Oral Forms

Lacosamide is available as both an oral tablet (and syrup) and an intravenous infusion. The IV form is typically used in hospital settings when someone cannot swallow, such as during or after a seizure. A bioequivalence study demonstrated that 30-minute and 60-minute IV infusions produce the same overall drug exposure as the equivalent oral dose.¹³ This means the elimination timeline does not change based on whether you received the drug by mouth or through a vein. You can switch from one to the other at the same dose without worrying that the drug will clear faster or slower.

Lacosamide is also rapidly and completely absorbed after oral dosing, so there is virtually no lag in getting the drug into your bloodstream compared with the IV route.⁹ From an elimination standpoint, the clock starts ticking at roughly the same time regardless of how the drug entered your body.

The Therapeutic Drug Monitoring Debate

Blood-level testing helps doctors verify that a patient has enough lacosamide on board to prevent seizures without having so much that side effects become a problem. The suggested target range for lacosamide has been revised over the years. The original reference range was 1 to 10 mg/L, but it was later updated to 10 to 20 mg/L. A study evaluating that newer range found that 41% of patients with levels in the 10 to 20 mg/L range reported adverse effects, compared to those without side effects whose average levels were lower. The researchers proposed capping the upper end of the target at 12 mg/L to balance seizure control with tolerability.¹⁴

This matters for the “how long does it stay in your system” question because the answer depends partly on what you mean by “in your system.” If you define it as being above the therapeutic threshold, that window is roughly one to two half-lives after your last dose. If you define it as being detectable at all by a sensitive lab assay, the window stretches to several days. And if your doctor is trying to keep your levels below a side-effect threshold, the timing of blood draws relative to your last dose (trough versus peak levels) changes the numbers you see on the lab report.

Pregnancy and Breastfeeding

For women taking lacosamide during pregnancy, serum concentrations appear to remain fairly stable throughout gestation, unlike some other anti-seizure medications that fluctuate dramatically as pregnancy-related changes in blood volume and metabolism kick in. After delivery, lacosamide passes into breast milk at a considerable rate, with a milk-to-serum ratio of about 0.83.¹⁵ That means the concentration in breast milk is roughly 83% of what is in the mother’s blood.

This high milk-to-serum ratio does not automatically mean breastfeeding is unsafe, but it does mean the nursing infant gets a meaningful exposure to the drug. Decisions about breastfeeding while on lacosamide involve weighing the benefits of breastfeeding against that exposure, and your neurologist and pediatrician should both be part of that conversation.

Genetic Variation in Drug Handling

Your genetic makeup can subtly influence how much lacosamide ends up in your bloodstream after a given dose. Research in pediatric epilepsy patients has identified specific variations in a gene called ABCB1, which codes for a protein that acts as a gatekeeper in the gut and brain. Certain versions of this gene were linked to significantly lower lacosamide blood levels, likely because the protein variant reduces absorption from the gastrointestinal tract.¹⁶

This kind of pharmacogenomic variability is not currently tested for in routine clinical practice when prescribing lacosamide. But it helps explain why two patients on the same dose can have noticeably different blood levels, and why some people seem to metabolize the drug faster than expected even after accounting for kidney function, liver health, and other medications. The field is still working out whether routine genetic testing would be useful enough to justify the cost, but awareness that these variants exist is growing.

What Happens in an Overdose

In a lacosamide overdose, the drug’s generally favorable clearance profile becomes a practical advantage because hemodialysis can speed up elimination when it counts. A reported case involved a woman whose lacosamide blood level on admission was 91.7 micrograms per milliliter, far above therapeutic concentrations. After developing seizures, she underwent four hours of hemodialysis, which dropped her level to 18.3 micrograms per milliliter and stopped the seizures.⁵ The drug’s relatively low binding to blood proteins makes it accessible to the dialysis filter, unlike some other anti-seizure medications that cling tightly to proteins and are harder to remove mechanically.

Outside of dialysis-assisted clearance, overdose management is largely supportive. There is no specific antidote. The body will eliminate lacosamide through its normal routes, but at toxic levels, the standard 13-hour half-life means dangerously high concentrations can persist for many hours. This is one situation where the question of how long the drug stays in your system takes on urgent clinical importance rather than being an abstract pharmacokinetic curiosity.

Children Clear Lacosamide Differently

Children are not just small adults when it comes to drug elimination. Lacosamide clearance in pediatric patients varies with body weight, and the effect of enzyme-inducing companion medications tends to be more dramatic in children than in adults.¹⁰ Population pharmacokinetic modeling has confirmed that body weight is one of the strongest predictors of how quickly a child clears lacosamide, with lighter children needing relatively higher weight-adjusted doses to achieve the same blood levels as heavier children or adults.¹¹

This faster clearance in smaller, younger patients means the effective half-life can be shorter than the 13-hour average seen in adults, and the drug may leave a child’s system somewhat faster than you would predict from adult data alone. Pediatric neurologists typically rely on therapeutic drug monitoring to dial in the right dose rather than trusting weight-based calculations alone, precisely because the variability between individual children is wide.